Transarterial embolization ablation of hepatocellular carcinoma with a lipiodol-ethanol mixture

Table 1 Demographic data

	n
Features
Sex (M/F)	13/2
Age (yr)	55.7 ± 10.3
Seropositive for HBsAg/HCV	15/0
Underlying cirrhosis (+/-)	13/2
Radiological/histological evidence of HCC	14/1
Newly diagnosed/refractory cases	5/10
Serum AFP level (μg/L)
≤ 200	2
> 200	13
Liver function status
Grade A/B	13/2
Feature of tumors
Single nodule1 ( ≤ 5 cm)	5
Huge lesion2 (> 5 cm)	5
Diffused lesion3	5

¹Patient with one tumor that was ≤ 5 cm in diameter;

²Patient with one tumor that was > 5 cm in diameter;

³Patient with multiple different size tumors. HBsAg: Hepatitis B surface antigen; HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; AFP: α fetoprotein.

Table 2 Clinical efficiency of newly diagnosed case

Newly diagnosed cases	Tumor response evaluation1		Follow-up period (mo)	Survival2
	Target lesion 2 mo post-TEA	Time to progress (mo)
1	CR	9.9	16.8	Yes
2	CR	6.1	14.1	Yes
3	PR	6.3	9.5	Yes
4	PR	5.1	7.5	Yes
5	PR	0	6.3	Yes

¹RECIST version 1.1;

²Survival (yes), death (no). TEA: Transarterial embolization ablation; CR: Complete response; PR: Partial response.

Table 3 Clinical efficiency of refractory cases

Refractory cases	Tumor response evaluation1		Follow-up period (mo)	Survival2
	Target lesion4 2 mo post-TEA	Time to progress (mo)
1	PR	6.5	8.1	No
2	PR	7.8	14.3	Yes
3	PR	4.2	7.1	No
4	SD	3.9	6.1	No
5	SD	3.7	4.9	No
6	PR	6.2	10.1	No
7	SD	3.0	5.1	No
8	PR	6.5	16.7	Yes
9	PR	5.0	9.9	No
10	PD	3	3.5	No

¹RECIST version 1.1;

²Survival (yes), death (no);

³Continued to progress;

⁴Percentage of response evaluation: CR (0%), PR (60%), SD (30%), PD (10%). TEA: Transarterial embolization ablation; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.

Table 4 Adverse events

Adverse events	n
Pain	15
Fever	11
Hepatic decompensation	10
Liver abscess	0
Biliary stricture or obstruction	0